Skip to main content
Livermore
Livermore
ZHEN

D. E. Shaw & Co., Inc.

SEC CIK
0001009207
Latest filing
Aug 14, 2026

RARE holding history

Ultragenyx Pharmaceutical Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

RARE overviewAll 13F holders of RAREFull Q2 2026 holdings

Shares (Q2 2026)
1,730,193
Value
$57.8M
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of RARE by D. E. Shaw & Co., Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20261,730,193$57.8M<0.1%+469,175+37.2%AddedHolders
Q1 20261,261,018$26.4M<0.1%+916,255+265.8%AddedHolders
Q4 2025344,763$7.93M<0.1%+107,123+45.1%AddedHolders
Q3 2025237,640$7.15M<0.1%−303,161−56.1%ReducedHolders
Q2 2025540,801$19.7M<0.1%−15,616−2.8%ReducedHolders
Q1 2025556,417$20.1M<0.1%+270,338+94.5%AddedHolders
Q4 2024286,079$12.0M<0.1%+24,485+9.4%AddedHolders
Q3 2024261,594$14.5M<0.1%+58,152+28.6%AddedHolders
Q2 2024203,442$8.36M<0.1%+203,442NewHolders
Q4 20230$00.0%−6,152−100.0%Sold outHolders
Q3 20236,152$219.3K<0.1%−88,777−93.5%ReducedHolders
Q2 202394,929$4.38M<0.1%−25,959−21.5%ReducedHolders
Q1 2023120,888$4.85M<0.1%−169,107−58.3%ReducedHolders
Q4 2022289,995$13.4M<0.1%−182,359−38.6%ReducedHolders
Q3 2022472,354$19.6M<0.1%+112,837+31.4%AddedHolders
Q2 2022359,517$21.4M<0.1%−124,821−25.8%ReducedHolders
Q1 2022484,338$35.2M<0.1%−62,253−11.4%ReducedHolders
Q4 2021546,591$46.0M0.1%+70,884+14.9%AddedHolders
Q3 2021475,707$42.9M0.1%−290,390−37.9%ReducedHolders
Q2 2021766,097$73.0M0.1%+14,929+2.0%AddedHolders
Q1 2021751,168$85.5M0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.